Managed Asset Portfolios LLC Invests $1.23 Million in Zoetis Inc. $ZTS

Managed Asset Portfolios LLC bought a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 8,400 shares of the company’s stock, valued at approximately $1,229,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. CIBC Asset Management Inc lifted its stake in Zoetis by 4.3% in the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after buying an additional 10,434 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp increased its stake in Zoetis by 6.5% during the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock worth $43,235,000 after buying an additional 18,040 shares in the last quarter. Ninety One UK Ltd raised its holdings in shares of Zoetis by 19.6% during the third quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock valued at $163,751,000 after acquiring an additional 183,686 shares during the last quarter. Quilter Plc lifted its position in shares of Zoetis by 10.2% in the third quarter. Quilter Plc now owns 438,959 shares of the company’s stock valued at $64,228,000 after acquiring an additional 40,615 shares in the last quarter. Finally, Swedbank AB boosted its stake in shares of Zoetis by 60.4% in the third quarter. Swedbank AB now owns 2,436,888 shares of the company’s stock worth $356,565,000 after acquiring an additional 917,598 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Trading Down 2.3%

Shares of ZTS stock opened at $126.01 on Wednesday. The company’s 50-day moving average price is $126.21 and its 200-day moving average price is $133.55. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The stock has a market cap of $53.19 billion, a price-to-earnings ratio of 20.93, a PEG ratio of 1.97 and a beta of 0.95. Zoetis Inc. has a twelve month low of $115.25 and a twelve month high of $177.00.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. During the same period last year, the business earned $1.40 earnings per share. Zoetis’s revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s payout ratio is presently 35.22%.

Analyst Ratings Changes

Several research analysts recently commented on the company. The Goldman Sachs Group raised Zoetis to a “buy” rating in a research note on Monday, December 15th. UBS Group set a $136.00 target price on shares of Zoetis in a report on Thursday, January 29th. William Blair reissued an “outperform” rating on shares of Zoetis in a research note on Monday. KeyCorp assumed coverage on shares of Zoetis in a research note on Thursday, November 20th. They set a “sector weight” rating for the company. Finally, JPMorgan Chase & Co. cut their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Six research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.